

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| | | |
|---|--|---|
| Antibodies | Yes (indicate where provided: | n/a |
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | | No lab work performed. No reagents used. |
| Cell materials | Yes (indicate where provided: | n/a |
| Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | No lab work performed. No cell lines used. |
| Primary cultures: Provide species, strain, sex of origin, genetic modification status. | | No lab work performed. No cell cultures used |
| Experimental animals | Yes (indicate where provided: | n/a |
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | This is retrospective observational study based on electronic medical records. No lab animals were |
| Animal observed in or captured from the field: Provide species, sex and age where possible | | This is retrospective observational study based on electronic medical |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | | This is retrospective observational study based on electronic medical records. No lab animals were used. |
| Plants and microbes | Yes (indicate where provided: | n/a |
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | This is retrospective observational study based on electronic medical records. No plants were used. |
| Microbes: provide species and strain, unique accession number if available, and source | | This is retrospective observational study based on electronic medical records. No microbes were used. |
| Human research participants | Yes (indicate where provided: | n/a |
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | WIRB Ref B4-Exemption-Moorthy (12-10-2018) | |
| Provide statement confirming informed consent obtained from study participants. | | Exemption criteria under 45 CFR §46.101(b)(4), which states that the following category of research is exempt from the requirements of 45 CFR 46: |
| Report on age and sex for all study participants. | See Table of demographics Table #3-page 12-line number 211-212 | |

Design

| | | |
|---|---|---|
| Study protocol | Yes (indicate where provided: | n/a |
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | This is retrospective observational study based on electronic medical records. |
| Laboratory protocol | Yes (indicate where provided: | n/a |
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | This is retrospective observational study based on electronic medical records. |
| Experimental study design (statistics details) | Yes (indicate where provided: | n/a |
| State whether and how the following have been done, or if they were not carried out. | | |
| Sample size determination | Page 4, line 104-106, Methodology, patient data, 1 st paragraph | |
| Randomization | | This is not a randomized study. |
| Blinding | | This is a retrospective study so no blinding was done. |
| Inclusion/exclusion criteria | Page 4, line 106-107, Methodology, patient data, 1 st paragraph | |
| Sample definition and in-laboratory replication | Yes (indicate where provided: | n/a |
| State number of times the experiment was replicated in laboratory | | No laboratory experiment was done. |
| Define whether data describe technical or biological replicates | | Data does not describe technical or biological replicate. |
| Ethics | Yes (indicate where provided: | n/a |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | This is a retrospective observational study with an exempt status. WIRB Ref B4-Exemption-Moorthy (12-10-2018) | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | No experimental animals were used. |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | No specimen and field samples were used. |
| Dual Use Research of Concern (DURC) | Yes (indicate where provided: | n/a |
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | This is a retrospective observational study with an exempt status. WIRB Ref B4-Exemption-Moorthy (12-10-2018) |

Analysis

| Attrition | Yes (indicate where) | n/a |
|---|--|---|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | | No one was excluded that were included in the analysis. |
| Statistics | Yes (indicate where) | n/a |
| Describe statistical tests used and justify choice of tests. | Section 2.5 Statistical analysis: page 9, line 174. Page 10 line 181-182 | |
| Data Availability | Yes (indicate where) | n/a |
| State whether newly created datasets are available, including protocols for access or restriction on access. | There is newly created dataset and access will be granted upon request by the primary corresponding author | |
| If data are publicly available, provide accession number in repository or DOI or URL. | | No public database available. |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | | No public database available. |
| Code Availability | Yes (indicate where) | n/a |
| For all newly generated code and software essential for replicating the main findings of the study: | | |
| State whether the code or software is available. | Methodology Page 5 line 135-136 Page 6 line 145-146 | |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | No code is publically available. |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|--|---|------------|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | | |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. | |

Article information: <http://dx.doi.org/10.21037/abs-20-103>